StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Oncotelic Therapeutics's price to sales ratio was 228.1× on Apr 30, 2024, against 6.8× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Apr 30, 2024228.1×+212.5
2021Apr 30, 202115.6×−19.0
2014Apr 30, 201434.6×+27.9
2013Oct 31, 20136.7×–

More Oncotelic Therapeutics figures

See a number that looks wrong?